BEST AVAILABLE COPY

AMENDMENTS TO THE CLAIMS

In the claims, please cancel claim 12 and amend claims 17 and 18 as follows:

- 1-10. (canceled)
- 11. (previously presented) A process for delivering an siRNA into a cell in a target tissue in a mammal, comprising:
 - a) mixing the siRNA and a compound selected from the group consisting of amphipathic compounds, polymers and non-viral vectors to form a complex wherein the zeta potential of the complex is less negative than the zeta potential of the siRNA alone;
 - b) inserting the complex into an efferent or afferent mammalian vessel of the target tissue in vivo thereby increasing permeability of vessels within the target tissue; and,
 - c) delivering the siRNA to the cell.
- 12. (canceled)
- 13. (original) The process of claim 12 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.
- 14. (original) The process of claim 13 wherein the cell is selected from the group consisting of liver cells, spleen cells, heart cells, kidney cells, prostate cells, skin cells, testis cells, skeletal muscle cells, fat, bladder cells, brain cells, pancreas cells, thymus cells, and lung cells.
- 15. (previously presented) The process of claim 11 wherein the complex has a positive charge.
- 16. (previously presented) The process of claim 11 wherein the complex has a negative charge.
- 17. (currently amended) The process of claim 13 wherein increasing the pressure consists of increasing volume of fluid within the vessel.
- 18. (currently amended) The process of ealim claim 17 wherein the solution is inserted within 2 minutes.

Respectfully submitted,

Kirk Ekena, Reg. No. 56,672 Mirus Bio Corporation

505 South Rosa Road Madison, WI 53719

608-238-4400

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

this dete: 11/21/2005.

Kirk Ekena